LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

This study is testing a new drug called LP-168 (a BTK inhibitor — a type of targeted therapy) combined with obinutuzumab (an antibody therapy) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has stopped responding to or relapsed after previous treatments including other BTK inhibitors. **You may be eligible if...** - You have been diagnosed with CLL or SLL that requires treatment - You have received at least one prior therapy (such as chemotherapy, a BCL2 inhibitor, or a BTK inhibitor) - You are 18 or older - You are in reasonably good health (ECOG 0 to 2) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have not received any prior treatment for CLL/SLL - You have severe liver or kidney problems outside acceptable study limits - You have uncontrolled active infections or other active cancers Talk to your doctor to see if this trial is right for you.